title: Inflammatory plasma markers and pancreatic cancer risk: a prospective study of five U.S. cohorts.
abstract: Chronic inflammation may play a role in the development of pancreatic cancer. However, few prospective studies have examined the association between plasma inflammatory markers and pancreatic cancer risk. Therefore, we investigated the association of prediagnostic circulating C-reactive protein (CRP), interleukin-6 (IL-6), and TNF-α receptor II (TNF-αR2) with subsequent pancreatic cancer risk in a prospective, nested case-control study of 470 cases and 1,094 controls from Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, Women's Health Initiative, and Women's Health Study. The median follow-up time of cases was 7.2 years (range 1-26 years). No association was observed between plasma CRP, IL-6, and TNF-αR2 and the risk of pancreatic cancer. Comparing extreme quintiles, the multivariate ORs were 1.10 [95% confidence interval (CI), 0.74-1.63; Ptrend = 0.81] for CRP, 1.19 (95% CI, 0.81-1.76; Ptrend = 0.08) for IL-6, and 0.88 (95% CI, 0.58-1.33; Ptrend = 0.57) for TNF-αR2. In conclusion, prediagnostic levels of circulating CRP, IL-6, and TNF-αR2 were not associated with the risk of pancreatic cancer, suggesting that systemic inflammation as measured by circulating inflammatory factors is unlikely to play a major role in the development of pancreatic cancer.
authors: Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA. ying.bao@channing.harvard.edu
authors: Ying
authors: Y
authors: Bao
authors: Edward L
authors: EL
authors: Giovannucci
authors: Peter
authors: P
authors: Kraft
authors: Zhi Rong
authors: ZR
authors: Qian
authors: Chen
authors: C
authors: Wu
authors: Shuji
authors: S
authors: Ogino
authors: J Michael
authors: JM
authors: Gaziano
authors: Meir J
authors: MJ
authors: Stampfer
authors: Jing
authors: J
authors: Ma
authors: Julie E
authors: JE
authors: Buring
authors: Howard D
authors: HD
authors: Sesso
authors: I-Min
authors: IM
authors: Lee
authors: Nader
authors: N
authors: Rifai
authors: Michael N
authors: MN
authors: Pollak
authors: Li
authors: L
authors: Jiao
authors: Lawrence
authors: L
authors: Lessin
authors: Barbara B
authors: BB
authors: Cochrane
authors: Joann E
authors: JE
authors: Manson
authors: Charles S
authors: CS
authors: Fuchs
authors: Brian M
authors: BM
authors: Wolpin
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D015331:Cohort Studies; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood* / Q000453:epidemiology; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000453:epidemiology; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
chemical_list: D014408:Biomarkers, Tumor; D015850:Interleukin-6; D002097:C-Reactive Protein